Top of this page
Skip navigation, go straight to the content
Rozanolixizumab (UCB7665)
| Disease area studied |
Abbreviated title | Phase | Study ID | Registry database | Study results | Lay summary | Publication (if available) |
|---|---|---|---|---|---|---|---|
| Chronic Inflammatory Demyelinating Polyradiculoneuropathy | A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy |
CIDP01 Ongoing |
|||||
| Chronic Inflammatory Demyelinating Polyradiculoneuropathy | A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy |
CIDP04 Ongoing |
|||||
| Myasthenia Gravis | A Multicenter, Randomized, Investigator- and Subject-Blind, Placebo-Controlled, Treatment Sequence Study Evaluating the Safety, Tolerability, and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis |
MG0002 Completed |
NCT03052751 2016-002698-36 |
Bril V., Neurology 2019; 92(15 suppl.), abs S43.001 | |||
| Myasthenia Gravis | A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis |
MG003 Ongoing |
|||||
| Myasthenia Gravis | A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis |
MG0004 Ongoing |
NCT04124965 | ||||
| Thrombocytopenia | Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia |
TP0001 Completed |
NCT02718716 2015-003984-12 |
Robak T., Jarque I., Musteata V., Kiessling P., Massow U. et al. Hemasphere 2018; 2(suppl.2):284–5. 23rd Congress of the European Hematology Association, EHA 2018; Stockholm, Sweden |